Barriers to achieving a cure in lymphoma

Abstract

Lymphoma is a diverse disease with a variety of different subtypes, each characterized by unique pathophysiology, tumor microenvironment, and underlying signaling pathways leading to oncogenesis. With our increasing understanding of the molecular biology of lymphoma, there have been a number of novel targeted therapies and immunotherapy approaches that have been developed for the treatment of this complex disease. Despite rapid progress in the field, however, many patients still relapse largely due to the development of drug resistance to these therapies. A better understanding of the mechanisms underlying resistance is needed to develop more novel treatment strategies that circumvent these mechanisms and design better treatment algorithms that personalize therapies to patients and sequence these therapies in the most optimal manner. This review focuses on the recent advances in therapies in lymphoma, including targeted therapies, monoclonal antibodies, antibody-drug conjugates, cellular therapy, bispecific antibodies, and checkpoint inhibitors. We discuss the genetic and cellular principles of drug resistance that span across all the therapies, as well as some of the unique mechanisms of resistance that are specific to these individual classes of therapies and the strategies that have been developed to address these modes of resistance.

Keywords

Lymphoma / drug resistance / novel therapies / targeted agents / immune therapies

References

[1] Tanaka S.B cell receptor signaling.Adv Exp Med Biol2020;1254:23-36

[2] Schmitz R,Huang DW.Genetics and pathogenesis of diffuse large B-cell lymphoma.N Engl J Med2018;378:1396-407 PMCID:PMC6010183

[3] Chapuy B,Dunford AJ.Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018;24:679-90 PMCID:PMC6613387

[4] Reddy A,Davis NS.Genetic and functional drivers of diffuse large B cell lymphoma.Cell2017;171:481-94.e15 PMCID:PMC5659841

[5] Wright GW,Phelan JD.A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications.Cancer Cell2020;37:551-68.e14 PMCID:PMC8459709

[6] Alizadeh AA,Davis RE.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature2000;403:503-11

[7] Xu-Monette ZY,Visco C.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.Blood2012;120:3986-96 PMCID:PMC3496956

[8] Song JY,Herrera AF.Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP.Clin Cancer Res2021;27:1671-80

[9] Rushton CK,Alcaide M.Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.Blood Adv2020;4:2886-98 PMCID:PMC7362366

[10] Pasqualucci L,Fabbri G.Analysis of the coding genome of diffuse large B-cell lymphoma.Nat Genet2011;43:830-7 PMCID:PMC3297422

[11] Steidl C,Woolcock BW.MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.Nature2011;471:377-81 PMCID:PMC3902849

[12] Verhoeven Y,Jacobs J.The potential and controversy of targeting STAT family members in cancer.Semin Cancer Biol2020;60:41-56

[13] Singh K.Functional implications of the spectrum of BCL2 mutations in lymphoma.Mutat Res Rev Mutat Res2016;769:1-18

[14] Dang CV,Juopperi T.The great MYC escape in tumorigenesis.Cancer Cell2005;8:177-8

[15] Rao E,Ji M.The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.Leukemia2012;26:1064-72

[16] Cascione L,Baudis M.DNA copy number changes in diffuse large B cell lymphomas.Front Oncol2020;10:584095 PMCID:PMC7740002

[17] Lenz G,Emre NC.Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.Proc Natl Acad Sci U S A2008;105:13520-5 PMCID:PMC2533222

[18] Bouska A,Lone W.Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.Blood2017;130:1819-31 PMCID:PMC5649549

[19] Jiang Y,Nie K.Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas.Genome Biol2014;15:432 PMCID:PMC4158101

[20] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[21] Klener P.Drug Resistance in non-Hodgkin lymphomas.Int J Mol Sci2020;21:2081 PMCID:PMC7139754

[22] Jazirehi AR.Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Oncogene2005;24:2121-43

[23] Torka P,Ferdman R.Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies.Curr Hematol Malig Rep2019;14:426-38

[24] Salles G,González Barca E.Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.Lancet Oncol2020;21:978-88

[25] Boxhammer R,Baumgartner R.Expression of CD19 antigen on chronic lymphocytic leukemia cells after tafasitamab (Anti-CD19) treatment: phase I trial data.Blood2019;134:5061

[26] Seymour JF,Eichhorst B.Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia.N Engl J Med2018;378:1107-20

[27] Al-sawaf O,Tandon M.Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2020;21:1188-200

[28] Zelenetz AD,Mason KD.Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.Blood2019;133:1964-76 PMCID:PMC6497517

[29] Davids MS,Seymour JF.Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma.J Clin Oncol2017;35:826-33 PMCID:PMC5455685

[30] Yue X,He J.Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies.Cancer Cell Int2020;20:524 PMCID:PMC7597043

[31] Jain N,Thompson P.Ibrutinib and venetoclax for first-line treatment of CLL.N Engl J Med2019;380:2095-103

[32] Thijssen R,Weller K.Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.Haematologica2015;100:e302-6 PMCID:PMC5004430

[33] Deng J,Fernandes SM,Letai A.Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.Leukemia2017;31:2075-84 PMCID:PMC5555835

[34] Cervantes-Gomez F,Woyach JA.Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia.Clin Cancer Res2015;21:3705-15 PMCID:PMC4537801

[35] Pleyer C,Sun C.Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.Leuk Lymphoma2018;59:2792-800 PMCID:PMC6237652

[36] Valla K,Koff JL.Targeting the B cell receptor pathway in non-Hodgkin lymphoma.Expert Opin Investig Drugs2018;27:513-22 PMCID:PMC6291828

[37] Woyach JA,Liu TM.Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.N Engl J Med2014;370:2286-94 PMCID:PMC4144824

[38] Epperla N,Jones D.Resistance mechanism for ibrutinib in marginal zone lymphoma.Blood Adv2019;3:500-2 PMCID:PMC6391658

[39] Xu L,Yang G.Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.Blood2017;129:2519-25 PMCID:PMC7484977

[40] Cao Y,Liu X.The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.Leukemia2015;29:169-76

[41] Treon SP,Guerrera ML.Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies.J Clin Oncol2020;38:1198-208 PMCID:PMC7351339

[42] Kanagal-Shamanna R,Patel KP.Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.Cancer2019;125:559-74

[43] George B,Hart A.Ibrutinib resistance mechanisms and treatment strategies for B-Cell lymphomas.Cancers (Basel)2020;12:1328 PMCID:PMC7281539

[44] Mato AR,Jurczak W.Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Lancet2021;397:892-901

[45] Kuo HP,Schweighofer KJ.Combination of ibrutinib and ABT-199 in diffuse large B-Cell lymphoma and follicular lymphoma.Mol Cancer Ther2017;16:1246-56

[46] Kapoor I,Sharma A.Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.Cell Death Dis2019;10:924 PMCID:PMC6892912

[47] Saba NS,Tanios G.MALT1 inhibition is efficacious in both Naïve and Ibrutinib-resistant chronic lymphocytic leukemia.Cancer Res2017;77:7038-48 PMCID:PMC5732856

[48] Kelly PN,Yang Y.Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.J Exp Med2015;212:2189-201 PMCID:PMC4689168

[49] Buchner M,Prinz G.Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.Cancer Res2009;69:5424-32

[50] Mondello P,De Stanchina E.Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.JCI Insight2017;2:e90196 PMCID:PMC5358483

[51] Brach D,Drew A.EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL.Mol Cancer Ther2017;16:2586-97

[52] Kittai AS,Thurlow B.SYK inhibitor entospletinib in combination with obinutuzumab demonstrates efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).Blood2019;134:4295

[53] Liu P,Roberts TM.Targeting the phosphoinositide 3-kinase pathway in cancer.Nat Rev Drug Discov2009;8:627-44 PMCID:PMC3142564

[54] Walsh K,Love C.PAK1 mediates resistance to PI3K inhibition in lymphomas.Clin Cancer Res2013;19:1106-15 PMCID:PMC3594365

[55] Kim JH,Park C.Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.BMC Cancer2019;19:936 PMCID:PMC6785854

[56] Choudhary GS,Mazumder S.MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.Cell Death Dis2015;6:e1593 PMCID:PMC4669737

[57] Phillips TJ,Ribrag V.Can Next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?.Clin Lymphoma Myeloma Leuk2021;21:8-20.e3

[58] de Vos S,Coutre SE.Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.Blood Adv2016;1:122-31 PMCID:PMC5737161

[59] Hwang BY,Chai H.Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris.J Org Chem2004;69:3350-8

[60] Zhang X,Lu T.Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.Leukemia2020;34:138-50 PMCID:PMC6895415

[61] Sanghvi VR,Singh K.NRF2 activation confers resistance to eIF4A inhibitors in cancer therapy.Cancers (Basel)2021;13:639 PMCID:PMC7915661

[62] Gupta SV,Davis ME.Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.AAPS J2011;13:357-64 PMCID:PMC3160166

[63] Thomas A,Hassan R.Antibody-drug conjugates for cancer therapy.Lancet Oncol2016;17:e254-62 PMCID:PMC6601617

[64] Straus DJ,Alekseev S.Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.Blood2020;135:735-42

[65] Horwitz S,Pro B.Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.Lancet2019;393:229-40 PMCID:PMC6436818

[66] Sehn LH,Flowers CR.Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.J Clin Oncol2020;38:155-65 PMCID:PMC7032881

[67] Caimi PF,Alderuccio JP.Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol2021;22:790-800

[68] Hamadani M,Caimi PF.Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.Lancet Haematol2021;8:e433-45

[69] Chen R,Hou J.Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma.Clin Cancer Res2020;26:1034-44 PMCID:PMC7056527

[70] Hochberg J.Resistance to antibody-drug conjugate. In: Xavier AC, Cairo MS, editors. Resistance to targeted therapies in lymphomas. Cham: Springer International Publishing; 2019. p. 57-69.

[71] Yu SF,Go M.A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs.Clin Cancer Res2015;21:3298-306

[72] Garcia-Alonso S,Pandiella A.Resistance to antibody-drug conjugates.Cancer Res2018;78:2159-65

[73] Chen R,Newman E.CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin.Mol Cancer Ther2015;14:1376-84 PMCID:PMC4458438

[74] Al-Rohil RN,Patel A.Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.J Cutan Pathol2016;43:1161-6

[75] Dornan D,Chen Y.Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.Blood2009;114:2721-9

[76] Chu Y,Wang X.Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.J Hematol Oncol2021;14:88 PMCID:PMC8180036

[77] Polson AG,Chan P.Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.Cancer Res2009;69:2358-64

[78] Neelapu SS,Bartlett NL.Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma.N Engl J Med2017;377:2531-44 PMCID:PMC5882485

[79] Schuster SJ,Tam CS.JULIET InvestigatorsTisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med2019;380:45-56

[80] Abramson JS,Gordon LI.Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet2020;396:839-52

[81] Jacobson CA,Sehgal AR.Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).J Clin Oncol2020;38:8008

[82] Wang M,Goy A.KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.N Engl J Med2020;382:1331-42 PMCID:PMC7731441

[83] Shah NN.Mechanisms of resistance to CAR T cell therapy.Nat Rev Clin Oncol2019;16:372-85 PMCID:PMC8214555

[84] Sotillo E,Black KL.Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy.Cancer Discov2015;5:1282-95 PMCID:PMC4670800

[85] Braig F,Goebeler M.Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.Blood2017;129:100-4

[86] Cheng J,Zhang Y.Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies.Front Oncol2019;9:1237 PMCID:PMC6882288

[87] Fry TJ,Orentas RJ.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med2018;24:20-8 PMCID:PMC5774642

[88] Ruella M,Kenderian SS.Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.J Clin Invest2016;126:3814-26 PMCID:PMC5096828

[89] Jacobson CA,Miklos DB.End of phase 1 results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma.Blood2018;132:4192

[90] Osborne W,Tholouli E.Phase I alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.J Clin Oncol2020;38:8001

[91] Yoon DH,Tolar J.Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T.Int J Mol Sci2018;19:340 PMCID:PMC5855562

[92] Berger TR.Mechanisms of response and resistance to CAR T cell therapies.Curr Opin Immunol2021;69:56-64

[93] Liu E,Banerjee P.Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.N Engl J Med2020;382:545-53 PMCID:PMC7101242

[94] Xie G,Liang Y,Rizwan R.CAR-NK cells: a promising cellular immunotherapy for cancer.EBioMedicine2020;59:102975 PMCID:PMC7452675

[95] Dufner V,Chatterjee M.Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.Blood Adv2019;3:2491-8 PMCID:PMC6712531

[96] Hutchings M,Iacoboni G.Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial.J Clin Oncol2021;39:1959-70 PMCID:PMC8210975

[97] Lejeune M,Duray E,Beguin Y.Bispecific, T-cell-recruiting antibodies in B-cell malignancies.Front Immunol2020;11:762 PMCID:PMC7221185

[98] Bachanova V,Cao Q.Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Clin Cancer Res2015;21:1267-72 PMCID:PMC4360883

[99] Topp MS,Stein AS.Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Oncol2015;16:57-66

[100] Duell J,Djuretic I.Bispecific antibodies in the treatment of hematologic malignancies.Clin Pharmacol Ther2019;106:781-91 PMCID:PMC6766786

[101] Duell J,Bedke T.Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.Leukemia2017;31:2181-90 PMCID:PMC5629361

[102] Feucht J,Gorodezki D.T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.Oncotarget2016;7:76902-19 PMCID:PMC5363558

[103] Bartlett NL,Domingo-Domenech E.A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.Blood2020;136:2401-9 PMCID:PMC7685206

[104] Ye Q,Poussin M.CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.Clin Cancer Res2014;20:44-55 PMCID:PMC3947326

[105] van Bommel PE,Schepel I.CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.Oncoimmunology2018;7:e1386361 PMCID:PMC5749665

[106] Armengol M,Fernández-Serrano M,Ribeiro ML.Immune-checkpoint inhibitors in B-cell lymphoma.Cancers (Basel)2021;13:214 PMCID:PMC7827333

[107] Veldman J,Berg AVD.Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.Cancer Treat Rev2020;82:101931

[108] De Re V, Caggiari L, Repetto O, Mussolin L, Mascarin M. Classical Hodgkin's lymphoma in the era of immune checkpoint inhibition.J Clin Med2019;8:1596 PMCID:PMC6832444

[109] Ansell S,Shipp MA.A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039).Blood2016;128:183

[110] Advani R,Popplewell L.CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma.N Engl J Med2018;379:1711-21 PMCID:PMC8058634

[111] Tobin JWD,Campbell A.PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma.Cells2021;10:1152 PMCID:PMC8151045

[112] Rothe A,Topp MS.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.Blood2015;125:4024-31 PMCID:PMC4528081

[113] Advani RH,Bartlett NL.Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.Blood2021;138:427-38

[114] Kurtz DM,Jin MC.Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma.J Clin Oncol2018;36:2845-53 PMCID:PMC6161832

[115] Roschewski M,Pittaluga S.Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.Lancet Oncol2015;16:541-9 PMCID:PMC4460610

[116] Bohers E,Becker S.Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.Blood Cancer J2018;8:74 PMCID:PMC6070497

[117] Sarkozy C,Carlton VE.The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.Oncotarget2017;8:8765-74 PMCID:PMC5352439

[118] Zohren F,Pechtel S.Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.Blood2015;126:1407-14

[119] Galimberti S,Ciabatti E.Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.Clin Cancer Res2014;20:6398-405

[120] Agarwal R,Tam CS.Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.Nat Med2019;25:119-29

[121] Spina V,Cuccaro A.Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.Blood2018;131:2413-25

[122] Pott C,Delfau-Larue MH.Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.Blood2010;115:3215-23 PMCID:PMC2930903

[123] Kolstad A,Eskelund CW.Nordic Lymphoma GroupMolecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years.Biol Blood Marrow Transplant2017;23:428-35

[124] Miljkovic MD,Pittaluga S.Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.Blood Adv2021;5:4198-210

[125] Frank MJ,Bukhari A.Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial.J Clin Oncol2021;39:3034-43

[126] Huet S.Potential of circulating tumor DNA for the management of patients with lymphoma.JCO Oncol Pract2020;16:561-8

[127] Jain N,Ferrajoli A,Mato AR.Approaches to chronic lymphocytic leukemia therapy in the era of new agents: the conundrum of many options.Am Soc Clin Oncol Educ Book2018;38:580-91

[128] Ghia P,Siddiqi T.Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of the FD cohort of the phase 2 captivate study.J Clin Oncol2021;39:7501